• Friday, 2 September
  • Saturday, 3 September
  • Sunday, 4 September
General Session
State-of-the-Art Lecture
Symposium
Industry Symposium
Workshop
TIME
08:00
09:30
ILCA Symposium 1: Prevention of Hepatocellular Carcinoma
C.L. Lai, MD, PhD (Hong Kong)

Does Antiviral Therapy for Hepatitis C Prevent Hepatocellular Carcinoma (HCC)?
Anna Lok, MD (USA)

Chemoprevention: Defining at Risk Populations for Trial Design
Jordi Bruix, MD (Spain)

09:30
10:30
State-of-the-Art Lecture 1: Noncoding RNA’s in Cancer Biology
Chair: Sheng-Long Ye, MD (P.R. China)
Speaker: Tushar Patel, MD (USA)
10:30
11:00
Coffee and Networking Break
11:00
11:15
Opening Ceremony
Gregory Gores, MD (USA)
Josep M. Llovet, MD (Spain/USA)
Jianren Gu, MD (P.R. China)
Masatoshi Kudo, MD, PhD (Japan)
11:15
12:45
General Session 1: Pathways and Gene Expression Profiles
Chairs: Xin Wang, MD, PhD (USA) and Jessica Zucmann-Rossi, MD, PhD (France)
12:45
13:00
Session Break
13:00
14:30
Bayer Lunch Symposium
14:30
16:00
General Session 2: Biomarkers, Diagnosis and Imaging
Chairs: Snorri Thorgeirsson, MD (USA) and Tania Roskams, MD (Belgium)
16:00
17:30
ILCA Symposium 2: The Cancer Microenvironment: A Less Complicated Target
Chairs: Gregory Gores, MD (USA) and Curtis Harris, MD, PhD (USA) Inflammation, Senescence and Tumour Suppression: Interweaving MicroRNA, Free Radical and p53 Networks
Curtis Harris, MD, PhD (USA)Anti-Angiogenesis Therapy
David Semela, MD, PhD (Switzerland)Myofibroblasts and Cancer Crosstalk
Gregory Gores, MD (USA)
17:30
17:45
Coffee and Networking Break
TIME
07:30
08:30
BMS Symposium
08:30
10:00
General Session 3: Curative Therapies
Chairs: Lun-Xiu Qin, MD, PhD (P.R. China) and Tadatoshi Takayama, MD, PhD (Japan)
10:00
10:30
Coffee and Networking Break
10:30
12:00
Plenary Session
Chairs: Gregory Gores, MD <emstyle=”color:#ffffff;”>(USA) and Irene Ng, MD, PhD <emstyle=”color:#ffffff;”> (Hong Kong)
12:00
12:15
Session Break
12:15
13:30
Luncheon workshop 1: Live Donor Liver Transplantation for HCC
Chairs: Norihiro Kokudo, MD, PhD (Japan) and Kim Olthoff, MD (USA)Luncheon workshop 2: Resection vs. Ablation for Small HCC 
Chairs: Masatoshi Kudo, MD, PhD (Japan) and Ronnie Poon, MD, PhD (P.R. China)Luncheon workshop 3: Liver Pathology in HCC; Biomarkers and Stratification
Chairs: Irene Ng, MD, PhD (Hong Kong) and Pierre Bedossa, MD, PhD (France)Luncheon workshop 4: Advanced HCC: Emerging Molecular Therapies
Chairs: Kwang-Hyub Han, MD (Korea) and Richard Finn, MD (USA)Luncheon workshop 5: What Can We Expect From Whole Genome Sequencing of HCC
Chairs: Derek Chiang, MD, PhD (USA) and J. Zucmann-Rossi, MD, PhD (France)
13:30
15:00
ILCA Symposium 3: Clinical Trials; Design and Pitfalls
Chairs: Josep M. Llovet, MD (Spain/USA) and Andrew Zhu, MD, PhD (USA)

Levels of Evidence: from Case Series to Pivotal Systematic Reviews
Christian Gluud, MD, PhD (Denmark)

Sources of Evidence: Phase III Studies vs. Meta-analysis
Andrew Zhu, MD, PhD (USA)

End-points and Regulatory Approval: Unmet Needs in HCC Management
Josep M. Llovet, MD (Spain/USA)

15:00
16:30
General Session 4: Locoregional Therapies and Response Assessment
Chairs: Riccardo Lencioni, MD (Italy) and Byung Ihn Choi, MD, PhD (Korea)
16:30
18:00
Poster Viewing Tour with a Welcome Reception
17:30
18:30
Biocompatibles Symposium
TIME
07:30
08:30
Sirtex Symposium
08:30
09:00
ILCA General Assembly
09:00
10:00
State of the Art Lecture 2: Beyond Receptor Thyronine Kinase: Alternative Treatment Strategies
Chair: Pierce Chow, MD (Singapore)
Speaker: Ann-Lii Cheng, MD, PhD (Taiwan)
10:00
11:30
General Session 5: Systemic Therapies
Chairs: Richard Finn, MD (USA) and Thomas Leung, MD (Hong Kong)
11:30
11:45
Closing Ceremony and Junior Investigator Awards
Gregory Gores, MD (USA)